港股異動 | 先聲藥業高開4% 3CL藥物開發進入全力衝刺階段 屬國內最快
格隆匯1月18日丨 先聲藥業(2096.HK)高開4.17%,報11.48港元,總市值303億港元,股價創近半年新高。消息面上,從先聲知情人士處瞭解到,先聲3CL藥物開發進入全力衝刺階段,主要進展有三個方面: 第一,CMC工藝開發環節已完成,正在生產臨牀樣品,與其他國產分子不同的是,0417分子特別適宜開發為口服藥物。 第二,GLP的猴子攻毒部分已全部完成給藥,屬國內最快。這是所有公司關鍵的限速步驟,因為國內做猴子攻毒研究一般排隊3-6個月,且擁有GLP的P3實驗室又只有三家,所以能夠在這麼短的時間裏來找到猴源,快速完成給藥部分,可見團隊運作效率之高。 第三,體內藥效顯示對野生株與delta株等都很好有抑制,劑量相關,肺部暴露量更高。對Omicron的藥效正在測試中,等待近期詳細結果,理論上3cl酶抑制活性對omicron突變影響不大。 先聲藥業亦對外明確透露有望4月中國獲批臨牀研究,也是唯一明確時間點的3CL項目。中科院藥物所是標準國家隊,先聲藥業成立20餘年,致力於快速創新轉型,在藥物開發與註冊步伐穩健,雙方合作,如能為國產新冠小分子藥物提供國產替代作出成績,將是利國利民之舉。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.